Results 211 to 220 of about 32,203 (276)

Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection for Early-Stage Breast Cancer and Sentinel Lymph Node Metastasis: An Updated Systematic Review and Meta-Analysis With Special Focus on Locoregional Recurrence and Regional Node Irradiation. [PDF]

Breast Cancer (Auckl)
Agrawal SK, Imran MM, Sethi S, Yadav SK, Agarwal P, Sharma D.   +5 more
europepmc   +1 more source

Supraclavicular Irradiation Induces Lymphedema in Breast Cancer Patients Treated with Axillary Lymph Node Dissection and Taxane-Containing Chemotherapy. [PDF]

Breast J
Horisawa N, Yoshimura A, Oze I, Sawaki M, Hattori M, Kotani H, Kataoka A, Ozaki Y, Nozawa K, Endo Y, Takatsuka D, Isogai A, Iwata H.   +12 more
europepmc   +1 more source

Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases. [PDF]

Cancers (Basel)
Houvenaeghel G, Heinemann M, Classe JM, Bouteille C, Gimbergues P, Azuar AS, Martino M, Tallet A, Cohen M, de Nonneville A.   +9 more
europepmc   +1 more source

Omission of axillary lymph node dissection in patients with breast cancer with axillary pathological complete response confirmed by stained region lymph node biopsy after neoadjuvant systemic therapy (SrLNB study): study protocol for a single-arm, single-centre, phase-II trial. [PDF]

BMJ Open
Ma L, Chen R, Wang M, Li X, Zheng R, Wang L, Ding J, Yao H, Gong Y, Wang Y, Sheng X, Wang J, Zha X.   +12 more
europepmc   +1 more source

An exploratory study of whether axillary lymph node dissection can be avoided in breast cancer patients with positive lymph nodes. [PDF]

Transl Cancer Res
Ren F, Yang C, Liu J, Feng K, Shang Q, Kang X, Zhang R, Li L, Zhao S, Wang X, Wang X.   +10 more
europepmc   +1 more source

Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. [PDF]

Cancer
Muslumanoglu M, Cabioglu N, Igci A, Karanlık H, Kocer HB, Senol K, Mantoglu B, Tukenmez M, Çakmak GK, Ozkurt E, Gulcelik MA, Emiroglu S, Mollavelioglu B, Yildirim N, Bademler S, Zengel B, Trabulus DC, Ugurlu MU, Uras C, Ilgun S, Akgul GG, Akcan A, Yormaz S, Ersoy YE, Ozbas S, Dilege E, Citgez B, Bolukbasi Y, Altınok A, Dag A, Basaran G, Utkan NZ, Ozcinar B, Arici C, AlJorani I, Kara H, Yigit B, Sen E, Erozgen F, Soyder A, Celik B, Kilic HG, Zer L, Sakman G, Yeniay L, Atahan K, Varol E, Veliyeva V, Goktepe B, Velidedeoglu M, Karaman N, Soran A, Aydiner A, Yılmaz R, Ibis K, Ozmen V.   +55 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND). [PDF]

Front Pharmacol
Brown S, Tadros AB, Montagna G, Bell T, Crowley F, Gallagher EJ, Dayan JH.   +6 more
europepmc   +1 more source